Literature DB >> 17028804

Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin.

Masaaki Mori1, Tomoyuki Imagawa, Shigeki Katakura, Takako Miyamae, Ken-Ichi Okuyama, Shuichi Ito, Tomoko Nakamura, Hirokazu Kimura, Shumpei Yokota.   

Abstract

Kawasaki disease (KD) causes coronary artery lesions (CALs) in 500 Japanese children each year. Intravenous gamma-globulin (IVGG) decreases the incidence of these lesions from 25% to 8% of the total KD cases. We examined whether plasma exchange is a safe and effective prophylaxis against CALs in children with KD intractable to IVGG therapy. Eighty-nine children with KD at high risk of CALs were selected on the basis of increases in fractional changes in inflammatory markers such as white blood cell count, neutrophil count, and C-reactive protein between the baseline and 1-2 days after IVGG treatment. Of 105 children who received a second course of IVGG therapy because the initial course was ineffective, plasma exchange (PE) was performed in 46 children who had not responded to the second IVGG treatment. The outcome was compared with the results when a third course of IVGG therapy was given to the other 59 children. No complications occurred with the plasma exchange therapy. CALs developed in only 8 of the 46 children (17.3%) who underwent plasma exchange, but they occurred in 24 of the 59 (40.7%) who had received a third course of IVGG therapy (P << 0.0012). We concluded that PE was a safe, effective prophylactic measure against CALs in children with KD intractable to IVGG therapy. PE should be performed at an early stage, as soon as fractional increases in inflammatory markers are found after IVGG therapy.

Entities:  

Year:  2004        PMID: 17028804     DOI: 10.1007/s10165-003-0264-3

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  19 in total

Review 1.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

Review 2.  Kawasaki disease: etiopathogenesis and novel treatment strategies.

Authors:  Shreya Agarwal; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-09-13       Impact factor: 4.473

3.  Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease.

Authors:  Eisuke Suganuma; Fumio Niimura; Shinichi Matsuda; Toshiko Ukawa; Hideaki Nakamura; Kaori Sekine; Masahiko Kato; Yuji Aiba; Yasuhiro Koga; Kuniyoshi Hayashi; Osamu Takahashi; Hiroyuki Mochizuki
Journal:  Pediatr Res       Date:  2016-12-20       Impact factor: 3.756

4.  Recent advances in the understanding and management of kawasaki disease.

Authors:  Anne H Rowley; Stanford T Shulman
Journal:  Curr Infect Dis Rep       Date:  2010-03       Impact factor: 3.725

5.  Resistance to intravenous immunoglobulin in children with Kawasaki disease.

Authors:  Adriana H Tremoulet; Brookie M Best; Sungchan Song; Susan Wang; Elena Corinaldesi; Julia R Eichenfield; Danielle D Martin; Jane W Newburger; Jane C Burns
Journal:  J Pediatr       Date:  2008-03-04       Impact factor: 4.406

6.  Kawasaki disease as a systemic vasculitis in childhood.

Authors:  Kei Takahashi; Toshiaki Oharaseki; Yuki Yokouchi; Nobuyuki Hiruta; Shiro Naoe
Journal:  Ann Vasc Dis       Date:  2010-12-02

Review 7.  Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a "protein homeostasis system".

Authors:  Kyung-Yil Lee; Jung-Woo Rhim; Jin-Han Kang
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

8.  Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease.

Authors:  Kei Takahashi; Toshiaki Oharaseki; Tomokazu Nagao; Yuki Yokouchi; Hitomi Yamada; Noriko Nagi-Miura; Naohito Ohno; Tsutomu Saji; Tomio Okazaki; Kazuo Suzuki
Journal:  Pediatr Rheumatol Online J       Date:  2011-09-29       Impact factor: 3.054

9.  Identification of candidate diagnostic serum biomarkers for Kawasaki disease using proteomic analysis.

Authors:  Yayoi Kimura; Masakatsu Yanagimachi; Yoko Ino; Mao Aketagawa; Michie Matsuo; Akiko Okayama; Hiroyuki Shimizu; Kunihiro Oba; Ichiro Morioka; Tomoyuki Imagawa; Tetsuji Kaneko; Shumpei Yokota; Hisashi Hirano; Masaaki Mori
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

10.  Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents.

Authors:  Ryuji Ohashi; Ryuji Fukazawa; Makoto Watanabe; Hanako Tajima; Noriko Nagi-Miura; Naohito Ohno; Shinichi Tsuchiya; Yuh Fukuda; Shunichi Ogawa; Yasuhiko Itoh
Journal:  Int J Vasc Med       Date:  2013-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.